Metabolomics and renal disease

Current Opinion in Nephrology and Hypertension

Volumn 24, Issue 4, 2015, Pages 371-379

  Rhee, Eugene P ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Metabolite profiling; Metabolomics; Renal metabolism

Indexed keywords

CREATININE; BIOLOGICAL MARKER;

CELL METABOLISM; CHRONIC KIDNEY DISEASE; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; END STAGE RENAL DISEASE; FOLLOW UP; GAS CHROMATOGRAPHY; GLOMERULUS FILTRATION; GLOMERULUS FILTRATION RATE; GLUCOSE METABOLISM; HUMAN; INTESTINE FLORA; KIDNEY CARCINOMA; KIDNEY DISEASE; KIDNEY FUNCTION; KIDNEY METABOLISM; KIDNEY POLYCYSTIC DISEASE; LIQUID CHROMATOGRAPHY; METABOLOMICS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; REVIEW; BLOOD; KIDNEY FUNCTION TEST; METABOLISM; PHENOTYPE; PROCEDURES; RENAL INSUFFICIENCY, CHRONIC;

BIOMARKERS; HUMANS; KIDNEY FUNCTION TESTS; METABOLOMICS; PHENOTYPE; RENAL INSUFFICIENCY, CHRONIC;

EID: 84942767071     PISSN: 10624821     EISSN: 14736543     Source Type: Journal    
DOI: 10.1097/MNH.0000000000000136     Document Type: Review

References (60)

1. Lindon JC, Holmes E, Bollard ME, et al. Metabonomics technologies and their applications in physiological monitoring, drug safety assessment and disease diagnosis. Biomarkers 2004;9:1-31.
2. Wishart DS, Knox C, Guo AC, et al. HMDB: a knowledgebase for the human metabolome. Nucleic Acids Res 2009;37:D603-D610.
3. Niwa T. Update of uremic toxin research by mass spectrometry. Mass Spectrom Rev 2011;30:510-521.
4. Vanholder R, De Smet R, Glorieux G, et al. Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int 2003;63:1934-1943.
5. Wishart DS. Metabolomics in monitoring kidney transplants. Curr Opin Nephrol Hypertens 2006;15:637-642.
6. Bohra R, Klepacki J, Klawitter J, et al. Proteomics and metabolomics in renal transplantation-quo vadis? Transpl Int 2013;26:225-241.
7. Wettersten HI, Weiss RH. Potential biofluid markers and treatment targets for renal cell carcinoma. Nat Rev Urol 2013;10:336-344.
8. Hanna MH, Brophy PD. Metabolomics in pediatric nephrology: emerging concepts. Pediatr Nephrol 2015;30:881-887; doi: 10.1007/s00467-014-2880. [Epub ahead of print]
9. Rhee EP, Gerszten RE. Metabolomics and cardiovascular biomarker discovery. Clin Chem 2012;58:139-147.
10. Patti GJ, Yanes O, Siuzdak G. Innovation: metabolomics: the apogee of the omics trilogy. Nat Rev Mol Cell Biol 2012;13:263-269.
11. German JB, Hammock BD, Watkins SM. Metabolomics: building on a century of biochemistry to guide human health. Metabolomics 2005;1:3-9.
12. Rhee EP, Souza A, Farrell L, et al. Metabolite profiling identifies markers of uremia. J Am Soc Nephrol 2010;21:1041-1051.
13. Sato E, Kohno M, Yamamoto M, et al. Metabolomic analysis of human plasma from haemodialysis patients. Eur J Clin Invest 2011;41:241-255.
14. Godfrey AR, Williams CM, Dudley E, et al. Investigation of uremic analytes in hemodialysate and their structural elucidation from accurate mass maps generated by a multidimensional liquid chromatography/mass spectrometry approach. Rapid Commun Mass Spectrom 2009;23:3194-3204.
15. Rhee EP, Thadhani R. New insights into uremia-induced alterations in metabolic pathways. Curr Opin Nephrol Hypertens 2011;20:593-598.
16. Toyohara T, Akiyama Y, Suzuki T, et al. Metabolomic profiling of uremic solutes in CKD patients. Hypertens Res 2010;33:944-952.
17. Goek ON, Doring A, Gieger C, et al. Serum metabolite concentrations and decreased GFR in the general population. Am J Kidney Dis 2012;60:197-206.
18. Shah VO, Townsend RR, Feldman HI, et al. Plasma metabolomic profiles in different stages of CKD. Clin J Am Soc Nephrol 2013;8:363-370.
19. Mutsaers HA, Engelke UF, Wilmer MJ, et al. Optimized metabolomicapproach to identify uremic solutes in plasma of stage 3-4 chronic kidney disease patients. PLoS One 2013;8:e71199.
20. Duranton F, Lundin U, Gayrard N, et al. Plasma and urinary amino acid & metabolomic profiling in patients with different levels of kidney function. Clin J Am Soc Nephrol 2014;9:37-45. Unlike most clinical metabolomics studies, this study examined paired plasma and urine samples from individuals across different stages of CKD, and plasma only from individuals with end-stage renal disease (ESRD). For metabolites that accumulate with falling eGFR, this study design allowed assessment of whether uremic metabolite elevation was attributable to decreased urinary clearance or increased metabolite production.
21. Posada-Ayala M, Zubiri I, Martin-Lorenzo M, et al. Identification of a urine metabolomic signature in patients with advanced-stage chronic kidney disease. Kidney Int 2014;85:103-111.
22. Yu B, Zheng Y, Nettleton JA, et al. Serum metabolomic profiling and incident & CKD among African Americans. Clin JAm Soc Nephrol 2014;9:1410-1417. Unlike prior large cohort-based metabolomics studies comprised predominantly of Caucasian study volunteers, this prospective study of incident CKD examined plasma from African-American individuals. Whether the different findings between this and prior studies reflect differences on the basis of race or other factors, however, is unclear.
23. Dungan KM. 1, 5-anhydroglucitol (GlycoMark) as a marker of short-term glycemic control and glycemic excursions. Expert Rev Mol Diagn 2008;8:9-19.
24. Rhee EP, Clish CB, Ghorbani A, et al. A combined epidemiologic and & metabolomic approach improves CKD prediction. J Am Soc Nephrol 2013;24:1330-1338. In conjunction with a case-control study of incident CKD, this study describes profiling of samples acquired from the aorta and renal vein of nine individuals. As discussed in the review, these findings expand our view of renal metabolite handling and have implications for the interpretation of metabolite biomarker studies.
25. Goek ON, Prehn C, Sekula P, et al. Metabolites associate with kidney function decline and incident chronic kidney disease in the general population. Nephrol Dial Transplant 2013;28:2131-2138.
26. Rhee EP, Feldman HI. Metabolite markers of incident CKD risk. Clin J Am Soc Nephrol 2014;9:1344-1346.
27. Pena MJ, Lambers Heerspink HJ, Hellemons ME, et al. Urine and plasma & metabolites predict the development of diabetic nephropathy in individuals with Type 2 diabetes mellitus. Diabet Med 2014;31:1138-1147. This study also profiled paired plasma and urine samples, in this case in a study of diabetic nephropathy progression, as defined by worsening proteinuria (either a transition from normoalbuminuria to microalbuminuria or from microalbuminuria to macroalbuminuria). This study design enabled comparison of the relative contribution of urine versus plasma metabolites to risk prediction.
28. Niewczas MA, Sirich TL, Mathew AV, et al. Uremic solutes and risk of end-stage renal disease in type 2 diabetes: metabolomic study. Kidney Int 2014;85:1214-1224. This is the first study to examine the relation between plasma metabolite levels and progression to ESRD. To what extent the risk markers identified in this study are specific to diabetic kidney disease and whether they are markers or effectors of disease progression require further study.
29. Sirich TL, Funk BA, Plummer NS, et al. Prominent accumulation in hemodialysis patients of solutes normally cleared by tubular secretion. J Am Soc Nephrol 2014;25:615-622.
30. Rhee EP, Clish CB, Pierce KA, et al. Metabolomics of renal venous plasma from individuals with unilateral renal artery stenosis and essential hypertension. J Hypertens 2015;33:836-842; doi: 10.1097/HJH.0000000000000470. [Epub ahead of print]
31. Sharma K, Karl B, Mathew AV, et al. Metabolomics reveals signature of mitochondrial dysfunction in diabetic kidney disease. J Am Soc Nephrol 2013;24:1901-1912. Using pathway analysis and protein-protein network analysis of urine metabolite data, this study implicates decreased mitochondrial function in human diabetic nephropathy. Importantly, studies of protein and mRNA expression in human tissue slices were performed to substantiate the metabolomic findings. Whether the urine metabolite signature differentiates diabetic and nondiabetic nephropathy, or whether it is able to predict disease progression, requires further study.
32. Dugan LL, You YH, Ali SS, et al. AMPK dysregulation promotes diabetesrelated reduction of superoxide and mitochondrial function. J Clin Invest 2013;123:4888-4899.
33. Stec DF, Wang S, Stothers C, et al. Alterations of urinary metabolite profile in model diabetic nephropathy. Biochem Biophys Res Commun 2015;456:610-614.
34. Kim JA, Choi HJ, Kwon YK, et al. 1H NMR-based metabolite profiling of plasma in a rat model of chronic kidney disease. PLoS One 2014;9:e85445.
35. Rowe I, Chiaravalli M, Mannella V, et al. Defective glucose metabolism in polycystic kidney disease identifies a new therapeutic strategy. Nat Med 2013;19:488-493. This impressive study developed from the simple observation that Pkd1 -/- cells acidify culture media more rapidly than wild-type cells, and found that Pkd1 deletion causes a switch to aerobic glucose metabolism, as is commonly observed in cancer cells. Intriguingly, inhibition of glycolysis was able to slow cyst grown in two murine models of PKD, demonstrating a fundamental role for this metabolic reprogramming in disease pathogenesis.
36. Priolo C, Henske EP. Metabolic reprogramming in polycystic kidney disease. Nat Med 2013;19:407-409.
37. Sun J, Shannon M, Ando Y, et al. Serum metabolomic profiles from patients with acute kidney injury: a pilot study. J Chromatogr B Analyt Technol Biomed Life Sci 2012;893-894:107-113.
38. Uehara T, Horinouchi A, Morikawa Y, et al. Identification of metabolomic biomarkers for drug-induced acute kidney injury in rats. J Appl Toxicol 2014;34:1087-1095.
39. Hanna MH, Segar JL, Teesch LM, et al. Urinary metabolomic markers of aminoglycoside nephrotoxicity in newborn rats. Pediatric Res 2013;73:585-591.
40. Schnackenberg LK, Sun J, Pence LM, et al. Metabolomics evaluation of hydroxyproline as a potential marker of melamine and cyanuric acid nephrotoxicity in male and female Fischer F344 rats. Food Chem Toxicol 2012;50:3978-3983.
41. Wei Q, Xiao X, Fogle P, Dong Z. Changes in metabolic profiles during acute kidney injury and recovery following ischemia/reperfusion. PLoS One 2014;9:e106647. This study provides tissue and temporal resolution of the metabolomic sequelae of IRI in mice. In addition to suggesting a change from glucose to lipid metabolism, this study demonstrates disturbed intrarenal osmolite metabolism and a lag in medullary metabolic recovery compared to cortex following IRI.
42. Ramezani A, Raj DS. The gut microbiome, kidney disease, and targeted interventions. J Am Soc Nephrol 2014;25:657-670.
43. Wikoff WR, Anfora AT, Liu J, et al. Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites. Proc Natl Acad Sci USA 2009;106:3698-3703.
44. Aronov PA, Luo FJ, Plummer NS, et al. Colonic contribution to uremic solutes. J Am Soc Nephrol 2011;22:1769-1776.
45. Le Poul E, Loison C, Struyf S, et al. Functional characterization of human receptors for short chain fatty acids and their role in polymorphonuclear cell activation. J Biol Chem 2003;278:25481-25489.
46. Chang PV, Hao L, Offermanns S, Medzhitov R. The microbial metabolite butyrate regulates intestinal macrophage function via histone deacetylase inhibition. Proc Natl Acad Sci USA 2014;111:2247-2252.
47. Pluznick JL, Zou DJ, Zhang X, et al. Functional expression of the olfactory signaling system in the kidney. Proc Natl Acad Sci USA 2009;106:2059-2064.
48. Pluznick JL, Protzko RJ, Gevorgyan H, et al. Olfactory receptor responding to gut microbiota-derived signals plays a role in renin secretion and blood pressure regulation. Proc Natl Acad Sci USA 2013;110:441 0-4415. A growing body of literature demonstrates the substantial contribution of the microbiome to the metabolome. This study is particularly notable because it outlines a signaling axis from gut to plasma to kidney through the specific interaction of SCFAs and select G-protein-coupled receptors.
49. Natarajan N, Pluznick JL. From microbe to man: the role of microbial short chain fatty acid metabolites in host cell biology. Am J Physiol Cell Physiol 2014;307:C979-C985.
50. Wang Z, Klipfell E, Bennett BJ, et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 2011;472:57-63.
51. Tang WH, Wang Z, Levison BS, et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Eng J Med 2013;368:1575-1584.
52. Bain MA, Faull R, Fornasini G, et al. Accumulation of trimethylamine and trimethylamine-N-oxide in end-stage renal disease patients undergoing haemodialysis. Nephrol Dial Transplant 2006;21:1300-1304.
53. Kalim S, Clish CB, Wenger J, et al. A plasma long-chain acylcarnitine predicts & cardiovascular mortality in incident dialysis patients. J Am Heart Assoc 2013;2:e000542. Although several studies have applied metabolomics to ESRD, this is the first study to relate metabolomics data to uremic cardiovascular risk. This study identifies an association between long-chain acylcarnitine levels and 1-year cardiovascular death in a study of 500 incident dialysis patients. No association was found for many previously established uremic toxins measured by the platform, including TMAO and indoxyl sulfate.
54. Cao XS, Chen J, Zou JZ, et al. Association of indoxyl sulfate with heart failure among patients on hemodialysis. Clin J Am Soc Nephrol 2015;10:111-119.
55. Vanholder R, Schepers E, Pletinck A, et al. The uremic toxicity of indoxyl sulfate and p-cresyl sulfate: a systematic review. J Am Soc Nephrol 2014;25:1897-1907.
56. Schulman G, Berl T, Beck GJ, et al. Randomized placebo-controlled EPPIC Trials of AST-120 in CKD. J Am Soc Nephrol 2014; doi: 10.1681/ASN.2014010042. [Epub ahead of print]
57. Mishima E, Fukuda S, Shima H, et al. Alteration of the intestinal environment by lubiprostone is associated with amelioration of adenine-induced CKD. J Am Soc Nephrol 2014; doi: 10.1681/ASN.2014060530. [Epub ahead of print]
58. Sirich TL, Plummer NS, Gardner CD, et al. Effect of increasing dietary fiber on plasma levels of colon-derived solutes in hemodialysis patients. Clin J Am Soc Nephrol 2014;9:1603-1610.
59. Fuhrer T, Zamboni N. High-throughput discovery metabolomics. Curr Opin Biotechnol 2015;31C: 73-78.
60. Atzler D, Schwedhelm E, Zeller T. Integrated genomics and metabolomics in nephrology. Nephrol Dial Transplant 2014;29:1467-1474.